Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial Article Full-text available
We report here the results of the Bone Trial of the Testosterone Trials (T-Trials), a group of 7 coordinated trials of the effects of testosterone treatment of older men with low testosterone concentrations. 23,24 The purpose of the Bone Trial was to determine whether testosterone treatment would improve vBMD and estimated bone strength.
Mar 14, 2014 · A number of studies have demonstrated the effect of testosterone on BMD in men with acquired hypogonadism or in aging men with low testosterone levels, although no data are available on fracture prevention. Behre et al. showed that testosterone therapy significantly increased BMD in 72 hypogonadal men regardless of age. They also found that BMD can be normalized and maintained …
The Bone Trial was rigorously designed to find out the effects of testosterone therapy on bone mineral density and estimated bone strength. 13 211 men 65 years or older with testosterone levels of 9.5 nmol/L (275 ng/dL) or less were randomized to receive treatment with either testosterone or …
hormonal mediators of appetite, bone mineral density and bone remodelling markers. placebo-controlled clinical trial response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial.
“The clinical significance of the effect of testosterone treatment on vBMD and estimated bone strength in these men will depend on whether testosterone treatment also reduces fracture risk,” Dr Snyder and colleagues wrote in the study. “Some evidence suggests that it might.
«After one year of treatment, older men with low testosterone significantly increased bone density and estimated bone strength compared to those on placebo,» said Dr. Wang. «A larger and longer
This prospective 2-year, single-center, randomized, placebo-controlled, open-label clinical trial was performed to evaluate the efficacy of low-dose testosterone undecanoate (TU) treatment on bone mineral density (BMD) and biochemical markers of bone turnover in elderly male osteoporosis with …
Decreased bone strength is a common and serious medical problem present in many people with anorexia nervosa. Men with anorexia nervosa have lower levels of gonadal steroids such as testosterone. Low testosterone levels have been shown to result in low bone density.
In both men and women, a decrease in bone mineral density (BMD) is a major symptom of hypogonadism. Although the effects of estrogens on osteoporosis in women are well documented, comparatively little is known about the effects of long term testosterone substitution on BMD in hypogonadal men.
For comparison, the scientists also measured bone mineral density in an untreated group of 70 women with normal ovarian function. Both hormone treatment regimens led to significant increases in the bone mineral density in the treatment groups.
all but four men in the testosterone group. Assessment of bone mineral density We measured bone mineral density in the lumbar spine (L2–L4) and three sites in the hip before treatment and after 6, 12, 24, and 36 months of treatment by dual energy x-ray absorptiometry using a Lunar Corp.
Published in: The Journal of Clinical Endocrinology and Metabolism · 1999Authors: Peter J Snyder · Helen Peachey · Peter Hannoush · Jesse A Berlin · Louise Loh · Joh…Affiliation: University of PennsylvaniaAbout: Biological activity · Dual-energy X-ray absorptiometry · Testosterone · Linear regression
Bone mineral density (BMD) is increased in transgender men and women following 1 year of cross-sex hormone treatment (CHT), according to research published in the Journal of Bone and Mineral …
Feb 21, 2017 · TUESDAY, Feb. 21, 2017 (HealthDay News) — Testosterone treatment can boost bone density and reduce anemia in older men with low levels of the hormone, but it …
Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial The exclusion criteria were outlined previously and included organic hypogonadism due to pituitary or testicular disease, contraindications to testosterone treatment, use of weight-altering medications including insulin, previous VLED failure and bariatric surgery. ..